Opportunity for Evaluation of Pharmaceutical Products – Antituberculosis Medicines
12 February 2024
The Global Fund invites manufacturers of pharmaceutical products to submit an Expression of Interest (EoI) to have their products evaluated by the Expert Review Panel for pharmaceutical products (ERP). This evaluation will focus particularly on Antituberculosis medicines:
- Rifapentine 150 mg, tablet (scored and dispersible)
- Rifapentine / Isoniazid / Moxifloxacin, 300 mg / 75 mg / 100mg tablet
- Rifapentine / Isoniazid / Moxifloxacin / Pyrazinamide, 300 mg / 75 mg / 100mg / 375 mg tablet
Detailed information about the review process and submission requirements can be found on the Expert Review Panel page.
This is an open invitation and the submission of an expression of interest is possible at any time.
Invitation to Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical Products
download in English